GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Mithra Pharmaceuticals SA (XBRU:MITRA) » Definitions » Capex-to-Revenue

Mithra Pharmaceuticals (XBRU:MITRA) Capex-to-Revenue : 0.80 (As of Jun. 2023)


View and export this data going back to 2015. Start your Free Trial

What is Mithra Pharmaceuticals Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

Mithra Pharmaceuticals's Capital Expenditure for the six months ended in Jun. 2023 was €-5.60 Mil. Its Revenue for the six months ended in Jun. 2023 was €7.04 Mil.

Hence, Mithra Pharmaceuticals's Capex-to-Revenue for the six months ended in Jun. 2023 was 0.80.


Mithra Pharmaceuticals Capex-to-Revenue Historical Data

The historical data trend for Mithra Pharmaceuticals's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mithra Pharmaceuticals Capex-to-Revenue Chart

Mithra Pharmaceuticals Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Capex-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.17 0.16 1.80 0.93 0.38

Mithra Pharmaceuticals Semi-Annual Data
Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Capex-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.86 1.02 1.08 0.24 0.80

Competitive Comparison of Mithra Pharmaceuticals's Capex-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Mithra Pharmaceuticals's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mithra Pharmaceuticals's Capex-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Mithra Pharmaceuticals's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where Mithra Pharmaceuticals's Capex-to-Revenue falls into.



Mithra Pharmaceuticals Capex-to-Revenue Calculation

Mithra Pharmaceuticals's Capex-to-Revenue for the fiscal year that ended in Dec. 2022 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-25.658) / 66.997
=0.38

Mithra Pharmaceuticals's Capex-to-Revenue for the quarter that ended in Jun. 2023 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-5.598) / 7.035
=0.80

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Mithra Pharmaceuticals  (XBRU:MITRA) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.


Mithra Pharmaceuticals Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of Mithra Pharmaceuticals's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Mithra Pharmaceuticals (XBRU:MITRA) Business Description

Traded in Other Exchanges
Address
Rue Saint-Georges 5, Liege, BEL, 4000
Mithra Pharmaceuticals SA develops products for women's health with a particular focus on fertility, contraception, and menopause. It operates in three segments: Product Sales, Out-licensing, and Other. The company also develops and markets complex therapeutic solutions and offers partners a complete spectrum of research, development, and specialist manufacturing at its Mithra CDMO. Its geographical segments are Belgium, Europe and Outside Europe.

Mithra Pharmaceuticals (XBRU:MITRA) Headlines

No Headlines